Published in Am J Med Sci on April 01, 2012
Problem pathogens: extra-intestinal complications of Salmonella enterica serotype Typhi infection. Lancet Infect Dis (2005) 2.67
The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2006) 2.60
Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol (2004) 1.98
Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer (2014) 1.98
The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol (2011) 1.86
Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther (2006) 1.84
Rifaximin--a novel antimicrobial for enteric infections. J Infect (2005) 1.79
Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol (2003) 1.77
Noroviruses: The leading cause of gastroenteritis worldwide. Discov Med (2010) 1.73
Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis (2009) 1.70
Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother (2010) 1.69
Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis (2002) 1.64
Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 1.63
Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother (2006) 1.62
Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. Ann Intern Med (2002) 1.61
A review of an emerging enteric pathogen: enteroaggregative Escherichia coli. J Med Microbiol (2006) 1.54
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol (2010) 1.50
Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg (2009) 1.49
Persistent abdominal symptoms in US adults after short-term stay in Mexico. J Travel Med (2014) 1.47
The role of diet in the treatment of travelers' diarrhea: a pilot study. Clin Infect Dis (2004) 1.45
Seroepidemiology of norovirus-associated travelers' diarrhea. J Travel Med (2014) 1.43
Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol (2007) 1.41
The controversial and short-lived early use of rehydration therapy for cholera. Clin Infect Dis (2008) 1.38
Enteroaggregative Escherichia coli is a cause of acute diarrheal illness: a meta-analysis. Clin Infect Dis (2006) 1.38
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther (2010) 1.35
Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother (2012) 1.33
Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis (2003) 1.30
Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J Infect Dis (2002) 1.25
Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis (2006) 1.21
Epidemiology of travelers' diarrhea: details of a global survey. J Travel Med (2004) 1.21
Association of diarrheagenic Escherichia coli Pathotypes with infection and diarrhea among Mexican children and association of atypical Enteropathogenic E. coli with acute diarrhea. J Clin Microbiol (2008) 1.21
Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli virulence factors in international travelers. J Clin Microbiol (2002) 1.19
A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother (2011) 1.18
Enteroaggregative Escherichia coli: an emerging enteric pathogen. Am J Gastroenterol (2004) 1.18
Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico. J Infect Dis (2002) 1.15
Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis (2008) 1.15
Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis (2007) 1.14
Pharmacist-managed vaccination program increased influenza vaccination rates in cardiovascular patients enrolled in a secondary prevention lipid clinic. Pharmacotherapy (2007) 1.14
Asymptomatic norovirus infection in Mexican children. J Clin Microbiol (2006) 1.13
Septal pouch in the left atrium: a new anatomical entity with potential for embolic complications. JACC Cardiovasc Interv (2010) 1.13
Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol (2014) 1.12
Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol (2009) 1.10
Association of putative enteroaggregative Escherichia coli virulence genes and biofilm production in isolates from travelers to developing countries. J Clin Microbiol (2006) 1.09
A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infect Dis (2007) 1.09
Drug-resistant diarrheogenic Escherichia coli, Mexico. Emerg Infect Dis (2005) 1.08
A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol (2006) 1.06
Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother (2012) 1.06
Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother (2012) 1.05
Involvement of immunization-certified pharmacists with immunization activities. Ann Pharmacother (2003) 1.05
Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol (2011) 1.05
Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. J Interv Card Electrophysiol (2013) 1.03
Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. J Clin Microbiol (2005) 1.03
Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican adults and US travelers in Mexico. J Travel Med (2002) 1.03
Virulence characteristics and the molecular epidemiology of enteroaggregative Escherichia coli isolates from travellers to developing countries. J Med Microbiol (2007) 1.03
Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic Escherichia coli. Clin Diagn Lab Immunol (2004) 1.02
Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis (2012) 1.02
Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis (2009) 0.99
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother (2008) 0.99
Associations between mucosal innate and adaptive immune responses and resolution of diarrheal pathogen infections. Infect Immun (2009) 0.98
Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother (2010) 0.97
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther (2005) 0.97
Impact of vitamin A on selected gastrointestinal pathogen infections and associated diarrheal episodes among children in Mexico City, Mexico. J Infect Dis (2006) 0.97
The search for effective treatment of Clostridium difficile infection. N Engl J Med (2011) 0.95
Effect of vitamin A and zinc supplementation on gastrointestinal parasitic infections among Mexican children. Pediatrics (2007) 0.94
In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. Antimicrob Agents Chemother (2010) 0.93
The effect of vitamin A supplementation on the intestinal immune response in Mexican children is modified by pathogen infections and diarrhea. J Nutr (2006) 0.93
Influence of host interleukin-10 polymorphisms on development of traveler's diarrhea due to heat-labile enterotoxin-producing Escherichia coli in travelers from the United States who are visiting Mexico. Clin Vaccine Immunol (2008) 0.93
Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico. J Clin Microbiol (2010) 0.92
Enterotoxigenic Escherichia coli heat-labile toxin seroconversion in US travelers to Mexico. J Travel Med (2008) 0.92
The patient presenting with acute dysentery--a systematic review. J Infect (2012) 0.92
Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis (2012) 0.91
Toxin synthesis by Clostridium difficile is regulated through quorum signaling. MBio (2015) 0.91
Advances in defining etiology and new therapeutic approaches in acute diarrhea. J Infect (2007) 0.91
Current and future developments in travelers' diarrhea therapy. Expert Rev Anti Infect Ther (2006) 0.91
A blueprint for transitioning pharmacy residents into successful clinical faculty members in colleges and schools of pharmacy. Am J Pharm Educ (2013) 0.90
Patterns of illness in travelers visiting Mexico and Central America: the GeoSentinel experience. Clin Infect Dis (2011) 0.90
Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to Noroviruses. J Med Virol (2006) 0.90
Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol (2004) 0.89
Mechanism of in vitro expansion of long DNA repeats: effect of temperature, repeat length, repeat sequence, and DNA polymerases. Biochemistry (2002) 0.89
Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone. J Travel Med (2007) 0.89
Noroviruses as a potential cause of protracted and lethal disease in immunocompromised patients. Clin Infect Dis (2009) 0.88
Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci (2003) 0.87
In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health (2011) 0.87
Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. AIDS Res Hum Retroviruses (2011) 0.87
Biosimilars 101: considerations for U.S. oncologists in clinical practice. Cancer Med (2014) 0.87
Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy. J Med Assoc Thai (2011) 0.86
Duplex and quadruplex DNA binding and photocleavage by trioxatriangulenium ion. Biochemistry (2005) 0.86
Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. Ann Pharmacother (2006) 0.85
Enterotoxigenic Escherichia coli and diffusely adherent E. coli as likely causes of a proportion of pathogen-negative travelers' diarrhea--a PCR-based study. J Travel Med (2008) 0.85
Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin (2007) 0.85
Seroprevalence of the enteroaggregative Escherichia coli virulence factor dispersin among USA travellers to Cuernavaca, Mexico: a pilot study. J Med Microbiol (2008) 0.85
Single nucleotide polymorphisms in the promoter of the gene encoding the lipopolysaccharide receptor CD14 are associated with bacterial diarrhea in US and Canadian travelers to Mexico. Clin Infect Dis (2011) 0.85
High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr Med Res Opin (2007) 0.84
A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol (2002) 0.84